RECVUE is a biotechnology company that develops and commercializes cell and gene therapies. The company's platform enables the development of novel cell and gene therapies by providing a comprehensive suite of tools for the design, engineering, and manufacturing of these therapies. RECVUE's technology is based on a proprietary gene editing platform that allows for precise and efficient editing of genes in cells. The company's mission is to improve patient outcomes by developing innovative therapies for a range of diseases, including cancer, genetic disorders, and autoimmune diseases.